Director, Global Medical AffairsSobi, Stockholm, SwedenStockholm, Stockholms Lan, Sweden
PB0213 - Efanesoctocog alfa vs. Standard Half-Life (Octocog Alfa) FVIII Therapies for Prophylaxis in Adolescents and Adults with Severe Hemophilia A: A Matching-Adjusted Indirect Comparison and Meta-Analysis
Sunday, June 25, 202318:30 – 19:30 ET
OC 69.5 - Outcomes in Adult and Adolescent Patients With Severe Hemophilia A in the Phase 3 XTEND-1 Study Who Switched to Efanesoctocog Alfa Prophylaxis From an Observational Study With Factor VIII Prophylaxis
Wednesday, June 28, 202311:15 – 11:30 ET
